Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 08, 2015 07:05 ET | Source: Galena Biopharma, Inc.

Galena Biopharma Provides 2015 Outlook

PORTLAND, Ore., Jan. 8, 2015 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address...
December 11, 2014 08:35 ET | Source: Galena Biopharma, Inc.

Galena Biopharma Presents HER2 Screening Data Including Preliminary Leica Bond Oracle(TM) Results From the Phase 3 NeuVax(TM) (nelipepimut-S) Clinical Trial at the 2014 San Antonio Breast Cancer Symposium (SABCS)

PORTLAND, Ore., Dec. 11, 2014 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address...
December 08, 2014 07:05 ET | Source: Galena Biopharma, Inc.

Galena Biopharma Presents GALE-401 (Anagrelide Controlled Release) Clinical Trial Data at the 56th American Society of Hematology (ASH) Annual Meeting & Exposition

Phase 1 results demonstrate GALE-401 reduces platelet counts with tolerable safety profile Preliminary Phase 2 clinical trial data show promising platelet response with top-line data to be...
December 05, 2014 07:05 ET | Source: Galena Biopharma, Inc.

Galena Biopharma to Present HER2 Screening Data From the Phase 3 NeuVax(TM) (nelipepimut-S) Clinical Trial at the 2014 San Antonio Breast Cancer Symposium (SABCS)

PORTLAND, Ore., Dec. 5, 2014 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address...
December 02, 2014 07:05 ET | Source: Galena Biopharma, Inc.

Galena Biopharma Receives Notice of Allowance of U.S. Patent Application for GALE-401 (Anagrelide Controlled Release) Composition of Matter

PORTLAND, Ore., Dec. 2, 2014 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address...
December 01, 2014 07:05 ET | Source: Galena Biopharma, Inc.

Galena Biopharma to Present GALE-401 (Anagrelide Controlled Release) Phase 1 Clinical Trial Data at the 56th American Society of Hematology (ASH) Annual Meeting & Exposition

PORTLAND, Ore., Dec. 1, 2014 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address...
November 25, 2014 07:05 ET | Source: Galena Biopharma, Inc.

Galena Biopharma to Present at the Oppenheimer 25th Annual Healthcare Conference

PORTLAND, Ore., Nov. 25, 2014 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address...
November 20, 2014 16:20 ET | Source: Galena Biopharma, Inc.

Galena Biopharma Announces Purchase Agreement for Up to $55.0 Million With Lincoln Park Capital Fund, LLC

Initial Purchase of $5.0 Million at $2.00 per share, 9% higher than the market close as of November 18, 2014 Agreement structure provides Galena control and flexibility to access capital over...
November 18, 2014 07:05 ET | Source: Galena Biopharma, Inc.

Galena Biopharma Completes Enrollment in GALE-401 (Anagrelide Controlled Release) Phase 2 Clinical Trial

Enrollment completed six months ahead of schedule Phase 1 and early Phase 2 data to be presented at the American Society of Hematology 56th Annual Meeting in December, with top-line data in...
November 13, 2014 07:05 ET | Source: Galena Biopharma, Inc.

Galena Biopharma to Present at the Stifel 2014 Healthcare Conference

PORTLAND, Ore., Nov. 13, 2014 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address...